These Money Losses Won't Help You at Tax Time
How to Save and Invest for a House Down Payment
8 Signs You're a Shopaholic and What to Do About It
Warren Buffett Turns 85: The Insider's Guide to His Empire
Is Celgene the Perfect Stock?
Merck has confirmed that it halted its late-stage student of vorapaxar, a potential clot-preventing drug, after an increased risk of bleeding in some patients.